7 results match your criteria: "Dongyang Affiliated Hospital of Wenzhou Medical University[Affiliation]"
Association analyses of nutritional markers with Parkinson's disease and Alzheimer's disease.
Heliyon
November 2024
Department of Neurology, Institute of Geriatric Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Article Synopsis
- - The study investigates the relationship between nutritional markers and the risk of Parkinson's disease (PD) and Alzheimer's disease (AD) among 424 PD patients, 314 AD patients, and 388 healthy controls.
- - Key findings reveal that higher levels of apolipoprotein B (ApoB), low-density lipoprotein (LDL), and total cholesterol (TC) are linked to a lower risk of PD, while homocysteine (HCY) levels increase the risk; for AD, ApoA1 shows protective effects, while HCY acts as a risk factor.
- - The results highlight the significance of lipid and one-carbon metabolism in the development of PD and AD, emphasizing the nutritional aspects that could influence these
Effect of coastal and island geographic environments on patients with acute ischemic stroke in southeastern China.
J Int Med Res
October 2024
Department of Neurology, Dongyang Affiliated Hospital of Wenzhou Medical University, Jinhua, China.
Article Synopsis
- The study investigates how geographic location affects the characteristics and treatment processes of patients with acute ischemic stroke (AIS) in southeastern China, comparing coastal, island, and inland areas.
- It analyzes data from over 8,000 AIS patients, finding that maritime hospitals have better access to therapies and shorter hospital processing times compared to inland hospitals.
- The findings highlight notable differences in stroke treatment across regions, suggesting the importance of tailored public health strategies to enhance stroke care and outcomes.
Safety of Antiplatelet Therapy in Noncardioembolic Ischemic Stroke With Thrombocytopenia: The CASE II Study.
J Am Heart Assoc
August 2024
Article Synopsis
- A study was conducted to evaluate the safety of antiplatelet therapy in acute ischemic stroke (AIS) patients who have low platelet counts (thrombocytopenia), as there is limited research on this topic.
- The research involved analyzing data from 169,423 AIS patients, ultimately focusing on 2,808 noncardioembolic patients with thrombocytopenia, comparing outcomes between those receiving antiplatelet therapy and those who did not.
- Results showed that antiplatelet therapy did not significantly increase the risk of severe bleeding and was associated with better functional outcomes at discharge and a potential trend towards lower mortality after one year.
Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features.
Stroke
June 2024
Department of Neurology, the Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China (H.Z., W.Z., T.Z., J.Y., M.L., S.Y.).
Background: Current evidence provides limited support for the superiority of endovascular thrombectomy (EVT) in patients with M2 segment middle cerebral artery occlusion. We aim to investigate whether imaging features of M2 segment occlusion impact the effectiveness of EVT.
Methods: We conducted a retrospective cohort study from January 2017 to January 2022, drawing data from the CASE II registry (Computer-Based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation), which specifically documented patients with acute ischemic stroke presenting with M2 segment occlusion undergoing reperfusion therapy.
Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration: A Randomized Clinical Trial.
JAMA Neurol
February 2024
Department of Neurology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Importance: The effect of argatroban in patients with acute ischemic stroke (AIS) and early neurological deterioration (END) is unknown.
Objective: To assess the efficacy of argatroban for END in AIS.
Design, Setting, And Participants: This open-label, blinded-end point, randomized clinical trial was conducted from April 4, 2020, through July 31, 2022.
Compositional and functional alterations of gut microbiota in patients with stroke.
Nutr Metab Cardiovasc Dis
November 2021
Department of Pathology, The Second Affiliated Hospital & Yuying Children´s Hospital of Wenzhou Medical University, Wenzhou, China. Electronic address:
Background And Aims: There is accumulating evidence that gut microbiota plays a key role in cardiovascular diseases. Gut bacteria can transform dietary choline, l-carnitine, and trimethylamine N-oxide (TMAO) into trimethylamine, which can be oxidized into TMAO again in the liver. However, the alterations of the gut microbiota in large artery atherosclerotic (LAA) stroke and cardioembolic (CE) stroke have been less studied.
View Article and Find Full Text PDFCombined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial.
J Neurol
July 2021
Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510630, China.
Objective: To investigate the safety and efficacy of intensive statin in the acute phase of ischemic stroke after intravenous thrombolysis therapy.
Methods: A total of 310 stroke patients treated with rt-PA were randomly scheduled into the intensive statin group (rosuvastatin 20 mg daily × 14 days) and the control group (rosuvastatin 5 mg daily × 14 days). The primary clinical endpoint was excellent functional outcome (mRS ≤ 1) at 3 months, and the primary safety endpoint was symptomatic intracranial hemorrhage (sICH) in 90 days.